• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Immune Pharmaceuticals, EpiCept complete merger

Immune Pharmaceuticals, EpiCept complete merger

August 26, 2013
CenterWatch Staff

Immune Pharmaceuticals has completed its merger with EpiCept. The merger combines Immune's antibody therapeutic platform focused on the treatment of inflammatory diseases and cancer with EpiCept's early-stage cancer program and its late-stage topical pain product, AmiKet.

Iin connection with the closing of the merger, the composition of the company's board of directors has increased to seven. Daniel Teper, chief executive officer, has joined the board of directors as chairman.  David Sidransky, professor of oncology at the Johns Hopkins School of Medicine, has been appointed vice chairman.  Ana Stancic has been named the chairperson of the audit committee. Isaac Kobrin, Herve de Kergrohen and Pierre Albouy also have been named to the company's board. 

Robert Cook, EpiCept's previous interim president and chief executive officer, retains his position on the board and has been named chief financial officer. Alan Dunton, previous non-executive chairman of EpiCept, Robert Savage and Keith Brownlie have resigned their positions.

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing